Le Coutre, P., Burchert, A., Saußele, S., Schwarzer, T., Stintzing, S., Pelzer, U., . . . Göthert, J. R. (2025). Favorable rates of cardiovascular events with stringent cardiovascular monitoring and a lowered dose of ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients failing or intolerant to first-line second-generation tyrosine kinase inhibitor treatment: Results of the prospective PONS trial. Acta haematologica. https://doi.org/10.1159/000545826
Chicago Style (17th ed.) CitationLe Coutre, Philipp, et al. "Favorable Rates of Cardiovascular Events with Stringent Cardiovascular Monitoring and a Lowered Dose of Ponatinib as Second-line Treatment in Chronic Phase Chronic Myeloid Leukemia Patients Failing or Intolerant to First-line Second-generation Tyrosine Kinase Inhibitor Treatment: Results of the Prospective PONS Trial." Acta Haematologica 2025. https://doi.org/10.1159/000545826.
MLA (9th ed.) CitationLe Coutre, Philipp, et al. "Favorable Rates of Cardiovascular Events with Stringent Cardiovascular Monitoring and a Lowered Dose of Ponatinib as Second-line Treatment in Chronic Phase Chronic Myeloid Leukemia Patients Failing or Intolerant to First-line Second-generation Tyrosine Kinase Inhibitor Treatment: Results of the Prospective PONS Trial." Acta Haematologica, 2025, https://doi.org/10.1159/000545826.